The presence of certain BRAF mutations (e.g., BRAFT1799A) in malignancies such as melanoma and lung cancer serves as a predictive biomarker for the clinical deployment of vertical inhibitors of BRAFV600E signaling [186]. Here, BRAF is linked to melanoma.